North America Digital Pathology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Type, Application, and End User

The digital pathology market in North America is expected to grow from US$ 361.14 million in 2022 to US$ 733.30 million by 2028. It is estimated to grow at a CAGR of 12.5% from 2022 to 2028.

Computerization, robotic light microscopy, multiple fiber-optic communications, and digital imaging are among the technologies contributing to the modernization of digital pathology. Healthcare information technology (IT) helps physicians in maintaining optimal workflow, along with allowing them to meet the continuously changing patient expectations. The Aperio ePathAccess software offered by Leica Biosystems enables users to share digital pathology images and case data with experts outside the IT network. Further, frequent advancements in whole-slide imaging (WSI) technology, software applications, LIS/LIMS interface, and high-speed networking are allowing pathologists to fully integrate digital pathology into their workflows. Further, the growing use of microarrays and predictive models, such as API algorithms and hybrid models, is bolstering the demand for digital image analysis. A computer-aided diagnosis integrates image processing with the concepts of physics and mathematics, and computational algorithms for disease diagnosis, anatomical evaluation, and disease progression quantification and risk assessment. Thus, the increasing popularity of computer-aided systems is supporting the digital pathology market growth in North America.

Market Overview

The North America digital pathology market is segmented into the US, Canada, and Mexico. North America held the largest share of the global market in 2022 owing to the growing initiatives to promote digital pathology as a tool for enhanced disease diagnosis and advanced pathology practice. Furthermore, organizations strive to promote digital pathology by spreading awareness about practicalities and strategies adopted for proper implementation and improvement of pathology workflows. FDA has cleared the use of digital pathology and whole slide imaging (WSI) system in primary diagnosis. In April 2017, first WSI system for digital pathology was allowed for primary diagnostic use in the US. This has helped pathologists to digitize the workflow and gather, store, and transfer patent’s data from remote places. A second system was authorized for marketing in the US in 2019. As a result, 100% of labs in the US are likely to go digital in the future. Many industry players are focusing on the digitization of pathology labs. Approval of WSI systems by the US FDA has enabled research institutes in the US to increase their efficiency and workflow. Thus, the increase in cancer cases in the US, benefits of digital pathology solutions, and cost and time reduction in pathology procedures are among the factors expected to drive the growth of the digital pathology systems market in the US during the forecast period.

North America Digital Pathology Market Segmentation

The North America digital pathology market is segmented on the basis of product, type, application, and end user. -Based on product, the North America digital pathology market is segmented into scanners, software, storage, and communication systems. The scanners segment held the largest market share in 2022. -Based on type, the North America digital pathology market is bifurcated into human pathology and veterinary pathology. The human pathology segment held a larger market share in 2022. -Based on application, the North America digital pathology market is segmented into drug discovery, disease diagnostics, teleconsultation, and training & education. The drug discovery segment held the largest market share in 2022. -Based on end user, the North America digital pathology market is segmented into pharma and biotech companies, hospitals, and academics. The pharma and biotech companies segment held the largest market share in 2022. -Based on country, the North America digital pathology market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.
Koninklijke Philips N.V.; Nikon Corporation; PerkinElmer, Inc.; Indica Labs; 3DHISTECH Ltd.; Hamamatsu Photonics K.K.; F. Hoffmann-La Roche Ltd; Visiopharm A/S; Glencoe Software, Inc.; and Danaher Corporation are among the leading companies operating in the digital pathology market in North America.